PPP1R14A Rabbit Polyclonal Antibody

CAT#: TA326034

Rabbit Polyclonal CPI17alpha Antibody



Need it in bulk or conjugated?
Get a free quote

CNY 1,999.00

CNY 3,280.00


货期*
2周

规格
    • 100 ul

Product images

经常一起买 (4)
Transient overexpression lysate of protein phosphatase 1, regulatory (inhibitor) subunit 14A (PPP1R14A)
    • 100 ug

CNY 3,080.00


beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human protein phosphatase 1, regulatory (inhibitor) subunit 14A (PPP1R14A), 20 µg
    • 20 ug

CNY 2,900.00
CNY 6,650.00


Recombinant protein of human protein phosphatase 1, regulatory (inhibitor) subunit 14A (PPP1R14A), 100 µg
    • 100 ug

CNY 9,998.00

Specifications

Product Data
Applications WB
Recommend Dilution WB: 1:500-1:2000; IHC: 1:50-1:200; IF/ICC: 1:100-1:500
Reactivity Human, Mouse, Rat
Host Rabbit
Clonality Polyclonal
Immunogen The antiserum was produced against A synthesized peptide derived from human CPI17alpha
Formulation Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Concentration lot specific
Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific peptide.
Conjugation Unconjugated
Storage Condition Store at -20°C as received.
Predicted Protein Size 22 kDa
Gene Name protein phosphatase 1 regulatory inhibitor subunit 14A
Background PPP1R14A a phosphorylation-dependent inhibitory subunit of protein phosphatase 1 (PP-1A). Phosphorylation by PKC regulates its binding to PP-1A. Acts co-operatively to inhibit myosin light chain phosphatase (MLCP) activity.
Synonyms CPI-17; CPI17; PPP1INL
Reference Data
Protein Families Druggable Genome
Protein Pathways Vascular smooth muscle contraction
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...